Morgan Stanley Downgrades Relypsa, Expects Focus To Return To The Challenged Veltassa Launch & Cash Burn

Loading...
Loading...

A review of the inspection document for ZS-9, launched by AstraZeneca plc (ADR) AZN, indicates that the FDA's concerns could be addressed within 4-6 months, resulting in rapid approval and competition for Veltassa’s launch by Relypsa Inc RLYP, Morgan Stanley’s Andrew S Berens said in a report.

The analyst downgraded the rating for Relypsa from Equal-weight to Underweight, while maintaining the price target at $9. He commented that the focus was likely to shift to the company’s challenged Veltassa launch and cash burn.

Since the upgrade to an Equal-weight rating by Morgan Stanley, Relypsa’s shares had appreciated ~35 percent, versus a 3 percent gain for the S&P 500). This makes the risk-reward profile unattractive, Berens stated.

Prospects Of Competing Drug

Once ZS-9 is approved and reaches the market, the drug could capture more than 80 percent of the hyperkalemia opportunity on account of its “better product profile, more viable commercial strategies, and a much lower expense basis” than Veltassa. The drug may also offer more favorable incentives to payors.

“We also think nearer-term competition decreases the likelihood of strategic optionality, as any potential interested party would likely decide to wait for the pending ZS-9 label to better understand the long-term commercial dynamics,” Berens wrote.

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorShort IdeasDowngradesAnalyst RatingsTrading IdeasAndrew S BerensMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...